Uptravi Range 200mg, 400mg, 600mg, 800mg, 1000mg, 1200mg, 1400mg, 1600mg FC tablets:
PDF Leaflet Revision Date: 17 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Long-term treatment of pulmonary arterial hypertension (PAH) in adults.
Dosage (summary)
Starting dose: 200 mcg twice daily, titrate up to 1600 mcg twice daily.
Special Populations
- Elderly (u2265 65 years)
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy not established; breastfeeding not recommended.
Key Drug Interactions
- Strong CYP2C8 inhibitors
- Anticoagulants
- Diuretics
Contraindications
- Hypersensitivity to selexipag
- Concomitant use of strong CYP2C8 inhibitors
Common side effects
- Headache
- Diarrhoea
- Nausea
- Vomiting
- Jaw pain
Counselling Points
- Take with or without food
- Do not split or chew tablets
- Monitor for thyroid function
Serious warnings
- Hyperthyroidism
- Pulmonary veno-occlusive disease
Important Disclaimer
The Uptravi Range 200mg, 400mg, 600mg, 800mg, 1000mg, 1200mg, 1400mg, 1600mg FC tablets: professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
